Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

NCT02287428 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma

Interventions

RADIATION: Radiation Therapy
BIOLOGICAL: Personalized NeoAntigen Peptides
DRUG: Pembrolizumab
DRUG: Temozolomide
DRUG: Temozolomide
BIOLOGICAL: Poly-ICLC

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]